Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530458 | 1.00 | NPSR1 (0.41) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL2530456 | 1.00 | NPSR1 (0.41) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL4841394 | 0.80 | NPSR1 (0.47) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL4841389 | 0.80 | NPSR1 (0.47) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL3576293 | 0.77 | NPSR1 (0.44) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL3576290 | 0.77 | NPSR1 (0.44) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL9806023 | 0.76 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL28134967 | 0.76 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL27541734 | 0.76 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL1234536 | 0.74 | NPSR1 (0.41) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-2190833-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis Ag (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20090312370-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2046761-A2 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009024615-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1968954-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008009750-A2 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312370-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | NPSR1 1992/4885GLO1 4153/4885ALDH1A1 3194/4885 |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | SLC10A2, SLC10A1, ASAH2 | NPSR1 3180/4885GLO1 4571/4885ALDH1A1 2955/4885 |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | NPSR1 621/4885GLO1 2423/4885ALDH1A1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.